Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 14/20 | 0.38 |
| ▸ | HTR2A | P28223 | 13/20 | 0.38 |
| ▸ | HTR2C | P28335 | 13/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29963760 | 1.00 | HTR2B (0.38) | HTR2BHTR2AHTR2CKDM1ABACE1 | |
| SCHEMBL26290504 | 1.00 | HTR2B (0.38) | HTR2BHTR2AHTR2CKDM1ABACE1 | |
| SCHEMBL21699940 | 1.00 | HTR2B (0.38) | HTR2BHTR2AHTR2CKDM1ABACE1 | |
| SCHEMBL13330120 | 1.00 | HTR2B (0.38) | HTR2BHTR2AHTR2CKDM1ABACE1 | |
| SCHEMBL3312184 | 1.00 | HTR2B (0.38) | HTR2BHTR2AHTR2CKDM1ABACE1 | |
| Hydrochloric Acid SCHEMBL29389941 | 0.98 | HTR2C (0.40) | HTR2BHTR2AHTR2CKDM1ABACE1 | |
| Mandelic Acid SCHEMBL29392712 | 0.83 | LMNA (0.39) | HTR2BHTR2AHTR2CBACE1 | |
| Mandelic Acid SCHEMBL30313545 | 0.83 | LMNA (0.39) | HTR2BHTR2AHTR2CBACE1 | |
| SCHEMBL1844188 | 0.81 | HTR2C (0.48) | HTR2BHTR2AHTR2CKDM1A | |
| SCHEMBL1844191 | 0.81 | HTR2C (0.48) | HTR2BHTR2AHTR2CKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3609891-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA CELLULAR THERAPIES INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250101022-A1 | PROCESS FOR PREPARING INTERMEDIATES FOR 1-(4-FLUOROPHENYL)-4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3’,4’:4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)BUTAN-1-ONE | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-12139490-B2 | Process for preparing 1-(4-fluorophenyl)-4-((6bR, 10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240327409-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2024-10-03 | — | — | US | disclosed |
| CN-113024554-B | Preparation method of rumepilone intermediate | 上海法默生物科技有限公司 | 2023-03-14 | — | — | CN | disclosed |
| US-20230009130-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20220332716-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-10-20 | — | — | US | disclosed |
| US-11453670-B2 | Substituted heterocycle fused gamma-carbolines synthesis | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-11407751-B2 | Hydrochloric acid salt of (6bR,10aS)-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxaline | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20220064166-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2022-03-03 | — | — | US | disclosed |
| US-20130046097-A1 | SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2013-02-21 | — | — | US | disclosed |
| US-8309722-B2 | Substituted heterocycle gamma-carbolines synthesis | INTRA-CELLULAR THERAPIES, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309722-B2 | Substituted heterocycle gamma-carbolines synthesis | INTRA-CELLULAR THERAPIES, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309722-B2 | Substituted heterocycle gamma-carbolines synthesis | INTRA-CELLULAR THERAPIES, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100113781-A1 | SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS | INTRACELLULAR THERAPIES, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113781-A1 | SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS | INTRACELLULAR THERAPIES, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113781-A1 | SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS | INTRACELLULAR THERAPIES, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| EP-2134710-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | Intra-Cellular Therapies, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008112280-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112280-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332716-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | HTR2B 952/4885HTR2A 1080/4885HTR2C 171/4885 |
| US-20240327409-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | HTR2B 1124/4885HTR2A 1243/4885HTR2C 233/4885 |
| US-20250101022-A1 | PROCESS FOR PREPARING INTERMEDIATES FOR 1-(4-FLUOROPHENYL)-4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3’,4’:4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)BUTAN-1-ONE | CYP1B1, CYP4B1, CBR1 | HTR2B 170/4885HTR2A 317/4885HTR2C 114/4885 |
| US-20100113781-A1 | SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS | CYCS, HCCS, CBR3 | HTR2B 467/4885HTR2A 557/4885HTR2C 72/4885 |
| US-11453670-B2 | Substituted heterocycle fused gamma-carbolines synthesis | HCCS, CYCS, CBR3 | HTR2B 1124/4885HTR2A 1243/4885HTR2C 233/4885 |
| US-20230009130-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | HTR2B 1124/4885HTR2A 1243/4885HTR2C 233/4885 |
| US-20130046097-A1 | SUBSTITUTED HETEROCYCLE GAMMA-CARBOLINES SYNTHESIS | CYCS, HCCS, CBR3 | HTR2B 467/4885HTR2A 557/4885HTR2C 72/4885 |
| US-11407751-B2 | Hydrochloric acid salt of (6bR,10aS)-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxaline | COX5B, IDH3B, CYP2J2 | HTR2B 12/4885HTR2A 82/4885HTR2C 22/4885 |
| US-20220064166-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | HTR2B 1124/4885HTR2A 1243/4885HTR2C 233/4885 |
| US-12139490-B2 | Process for preparing 1-(4-fluorophenyl)-4-((6bR, 10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one | CYP1B1, CYP4B1, CBR1 | HTR2B 74/4885HTR2A 143/4885HTR2C 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.